Chinese authorities granted Jiangsu Hengrui Medicine (SHA:600276) subsidiary Tianjin Hengrui Medicine clinical trial approval for its metazol injection, according to a Thursday filing with the Shanghai Stock Exchange.
The drug is used for radioactive diagnosis for brain positron emission tomography imaging, especially for patients with cognitive conditions such as Alzheimer's disease or other conditions, the filing said.
Shares rose 1% during recent trade.
Price (RMB): ¥44.25, Change: ¥+0.41, Percent Change: +0.94%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments